Loading…
Reported covered position: N/A
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Competitive DRUGS Act of 2019
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to the Rare Pediatric Disease Priority Review Voucher Program. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HSA/FSA provisions. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
BAYER CORPORATION (CONSOLIDATED REPORT) via BAYER CORPORATION (CONSOLIDATED REPORT)
2020 · fourth_quarter · Q4
Monitor legislative and federal activity related to tax reform. Monitor legislative and administrative action related to corporate and international tax, including issues related to tax code sections 172, 245A, 951A, and 965. Monitor legislative and administrative action related to implementation of P.L. 115-97, Tax Cuts and Jobs Act. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act). H.R. 1922, Restoring Access to Medication Act of 2019.
Source: Senate LDA
Competitive DRUGS Act of 2019
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HAS/FSA provisions. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
Competitive DRUGS Act of 2019
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to the Rare Pediatric Disease Priority Review Voucher Program. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HSA/FSA provisions. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
Competitive DRUGS Act of 2019
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HASA/FSA provisions. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
Competitive DRUGS Act of 2019
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HAS/FSA provisions. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
Orange Book Transparency Act of 2020
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to the Rare Pediatric Disease Priority Review Voucher Program. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HSA/FSA provisions. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
Orange Book Transparency Act of 2020
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HAS/FSA provisions. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
Orange Book Transparency Act of 2020
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to the Rare Pediatric Disease Priority Review Voucher Program. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HSA/FSA provisions. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
Orange Book Transparency Act of 2020
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HASA/FSA provisions. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
Orange Book Transparency Act of 2020
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HAS/FSA provisions. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
Further Extension of Continuing Appropriations Act, 2021
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to the Rare Pediatric Disease Priority Review Voucher Program. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HSA/FSA provisions. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
Further Extension of Continuing Appropriations Act, 2021
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HAS/FSA provisions. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
Further Extension of Continuing Appropriations Act, 2021
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to the Rare Pediatric Disease Priority Review Voucher Program. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HSA/FSA provisions. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
Further Extension of Continuing Appropriations Act, 2021
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HASA/FSA provisions. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
Further Extension of Continuing Appropriations Act, 2021
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HAS/FSA provisions. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
Restoring Access to Medication Act of 2019
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and federal activity related to tax reform. Monitor legislative and administrative action related to corporate and international tax, including issues related to tax code sections 172, 245A, 951A, and 965. Monitor legislative and administrative action related to implementation of P.L. 115-97, Tax Cuts and Jobs Act. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act). H.R. 1922, Restoring Access to Medication Act of 2019.
Restoring Access to Medication Act of 2019
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and federal activity related to tax reform. Monitor legislative and administrative action related to corporate and international tax, including issues related to tax code sections 172, 245A, 951A, and 965. Monitor legislative and administrative action related to implementation of P.L. 115-97, Tax Cuts and Jobs Act. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act). H.R. 1922, Restoring Access to Medication Act of 2019.
Restoring Access to Medication Act of 2019
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and federal activity related to tax reform. Monitor legislative and administrative action related to implementation of P.L. 115-97, Tax Cuts and Jobs Act. H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act). H.R. 1922, Restoring Access to Medication Act of 2019.
Restoring Access to Medication Act of 2019
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and federal activity related to tax reform. Monitor legislative and administrative action related to corporate and international tax, including issues related to tax code sections 172, 245A, 951A, and 965. Monitor legislative and administrative action related to implementation of P.L. 115-97, Tax Cuts and Jobs Act. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act). H.R. 1922, Restoring Access to Medication Act of 2019.
Restoring Access to Medication Act of 2019
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and federal activity related to tax reform. Monitor legislative and administrative action related to implementation of P.L. 115-97, Tax Cuts and Jobs Act. H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act). H.R. 1922, Restoring Access to Medication Act of 2019.
Elijah E. Cummings Lower Drug Costs Now Act
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to the Rare Pediatric Disease Priority Review Voucher Program. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HSA/FSA provisions. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
Elijah E. Cummings Lower Drug Costs Now Act
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HAS/FSA provisions. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
Elijah E. Cummings Lower Drug Costs Now Act
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to the Rare Pediatric Disease Priority Review Voucher Program. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HSA/FSA provisions. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
Elijah E. Cummings Lower Drug Costs Now Act
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HASA/FSA provisions. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
Elijah E. Cummings Lower Drug Costs Now Act
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HAS/FSA provisions. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
CARES Act
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and federal activity related to tax reform. Monitor legislative and administrative action related to implementation of P.L. 115-97, Tax Cuts and Jobs Act. H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act). H.R. 1922, Restoring Access to Medication Act of 2019.
CARES Act
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HAS/FSA provisions. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
CARES Act
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and federal activity related to tax reform. Monitor legislative and administrative action related to implementation of P.L. 115-97, Tax Cuts and Jobs Act. H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act). H.R. 1922, Restoring Access to Medication Act of 2019.
CARES Act
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HAS/FSA provisions. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
DXM Abuse Prevention Act of 2019
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to the Rare Pediatric Disease Priority Review Voucher Program. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HSA/FSA provisions. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
DXM Abuse Prevention Act of 2019
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HAS/FSA provisions. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
DXM Abuse Prevention Act of 2019
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to the Rare Pediatric Disease Priority Review Voucher Program. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HSA/FSA provisions. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
DXM Abuse Prevention Act of 2019
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HASA/FSA provisions. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
DXM Abuse Prevention Act of 2019
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HAS/FSA provisions. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
CREATES Act of 2019
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to the Rare Pediatric Disease Priority Review Voucher Program. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HSA/FSA provisions. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
CREATES Act of 2019
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HAS/FSA provisions. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
CREATES Act of 2019
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to the Rare Pediatric Disease Priority Review Voucher Program. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HSA/FSA provisions. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
CREATES Act of 2019
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HASA/FSA provisions. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
CREATES Act of 2019
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HAS/FSA provisions. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
FAST Generics Act of 2019
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to the Rare Pediatric Disease Priority Review Voucher Program. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HSA/FSA provisions. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
FAST Generics Act of 2019
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HAS/FSA provisions. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
FAST Generics Act of 2019
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to the Rare Pediatric Disease Priority Review Voucher Program. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HSA/FSA provisions. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
FAST Generics Act of 2019
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HASA/FSA provisions. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
FAST Generics Act of 2019
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HAS/FSA provisions. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
Prescription Drug Pricing Reduction Act of 2019
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to the Rare Pediatric Disease Priority Review Voucher Program. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HSA/FSA provisions. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
Prescription Drug Pricing Reduction Act of 2019
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HAS/FSA provisions. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
Prescription Drug Pricing Reduction Act of 2019
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to the Rare Pediatric Disease Priority Review Voucher Program. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HSA/FSA provisions. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
Prescription Drug Pricing Reduction Act of 2019
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HASA/FSA provisions. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
Prescription Drug Pricing Reduction Act of 2019
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HAS/FSA provisions. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to the Rare Pediatric Disease Priority Review Voucher Program. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HSA/FSA provisions. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HAS/FSA provisions. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to the Rare Pediatric Disease Priority Review Voucher Program. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HSA/FSA provisions. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HASA/FSA provisions. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HAS/FSA provisions. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to the Rare Pediatric Disease Priority Review Voucher Program. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HSA/FSA provisions. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
Filing targets: Agriculture, Dept of (USDA), Bureau of Land Management (BLM), Commerce, Dept of (DOC), Council on Environmental Quality (CEQ), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR), White House Office
BAYER CORPORATION (CONSOLIDATED REPORT) via BAYER CORPORATION (CONSOLIDATED REPORT)
2020 · third_quarter · Q3
Monitor legislative and federal activity related to tax reform. Monitor legislative and administrative action related to corporate and international tax, including issues related to tax code sections 172, 245A, 951A, and 965. Monitor legislative and administrative action related to implementation of P.L. 115-97, Tax Cuts and Jobs Act. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act). H.R. 1922, Restoring Access to Medication Act of 2019.
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to the Rare Pediatric Disease Priority Review Voucher Program. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HSA/FSA provisions. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
Filing targets: Agriculture, Dept of (USDA), Bureau of Land Management (BLM), Commerce, Dept of (DOC), Council on Environmental Quality (CEQ), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR), White House Office
BAYER CORPORATION (CONSOLIDATED REPORT) via BAYER CORPORATION (CONSOLIDATED REPORT)
2020 · second_quarter · Q2
Monitor legislative and federal activity related to tax reform. Monitor legislative and administrative action related to corporate and international tax, including issues related to tax code sections 172, 245A, 951A, and 965. Monitor legislative and administrative action related to implementation of P.L. 115-97, Tax Cuts and Jobs Act. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act). H.R. 1922, Restoring Access to Medication Act of 2019.
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HASA/FSA provisions. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
Filing targets: Agriculture, Dept of (USDA), Bureau of Land Management (BLM), Commerce, Dept of (DOC), Council on Environmental Quality (CEQ), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR), White House Office
BAYER CORPORATION (CONSOLIDATED REPORT) via BAYER CORPORATION (CONSOLIDATED REPORT)
2020 · first_quarter · 1A
Monitor legislative and federal activity related to tax reform. Monitor legislative and administrative action related to implementation of P.L. 115-97, Tax Cuts and Jobs Act. H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act). H.R. 1922, Restoring Access to Medication Act of 2019.
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HAS/FSA provisions. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
Filing targets: Agriculture, Dept of (USDA), Bureau of Land Management (BLM), Commerce, Dept of (DOC), Council on Environmental Quality (CEQ), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, Small Business Administration (SBA), State, Dept of (DOS), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
BAYER CORPORATION (CONSOLIDATED REPORT) via BAYER CORPORATION (CONSOLIDATED REPORT)
2020 · first_quarter · Q1
Monitor legislative and federal activity related to tax reform. Monitor legislative and administrative action related to implementation of P.L. 115-97, Tax Cuts and Jobs Act. H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act). H.R. 1922, Restoring Access to Medication Act of 2019.
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HAS/FSA provisions. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
Filing targets: Agriculture, Dept of (USDA), Bureau of Land Management (BLM), Commerce, Dept of (DOC), Council on Environmental Quality (CEQ), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, Small Business Administration (SBA), State, Dept of (DOS), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)